These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33410523)

  • 1. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
    Groarke EM; Patel BA; Gutierrez-Rodrigues F; Rios O; Lotter J; Baldoni D; St Pierre A; Shalhoub R; Wu CO; Townsley DM; Young NS
    Br J Haematol; 2021 Feb; 192(3):605-614. PubMed ID: 33410523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
    Patel BA; Groarke EM; Lotter J; Shalhoub R; Gutierrez-Rodrigues F; Rios O; Quinones Raffo D; Wu CO; Young NS
    Blood; 2022 Jan; 139(1):34-43. PubMed ID: 34525188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag in children with severe aplastic anemia.
    Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
    Jin Y; Li R; Lin S; Jia J; Yang Y; Zhang D; He G; Li J
    Ann Hematol; 2022 Nov; 101(11):2413-2419. PubMed ID: 36028583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence.
    Li X; Shangguan X; Wang H; Wang Q; Zhang Y; Han B; Liu R; Zhang F; Fu R; Lin Z; Miao M; Ma X; Lei M; Wu D; Liu L
    Ann Hematol; 2024 Sep; 103(9):3483-3491. PubMed ID: 39088061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
    Huang LF; Li L; Jia JS; Yang Y; Lin SY; Meng FK; Zhang DH; He GS
    Transplant Cell Ther; 2022 Sep; 28(9):586.e1-586.e7. PubMed ID: 35609866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study.
    Fang M; Song H; Zhang J; Li S; Shen D; Tang Y
    Pediatr Hematol Oncol; 2021 Oct; 38(7):633-646. PubMed ID: 33724146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.
    Liu L; Han B; Zhang Y; Lei M; Liu R; Lin Z; Jiao W; Zhang F; Fu R; Zhao X; Miao M; Zhang L; Wu D
    Bone Marrow Transplant; 2024 Oct; 59(10):1449-1457. PubMed ID: 39090437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
    Zhang Y; Li J; Li X; Geng Q; Xie Y; Zhang G; Wei M; Ma Y
    Syst Rev; 2024 Apr; 13(1):101. PubMed ID: 38576005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
    Hwang YY; Chan TSY; Chan FHY; Lau CWP; Luk YY; Lau GWN; Chan KP; Leung KH; Kho B; Lau JSM; Lau CK; Mak V; Yip SF; Lin SY; Sim JPY; Kwong YL
    Ann Hematol; 2022 Jun; 101(6):1163-1172. PubMed ID: 35412083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
    Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
    Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
    [No Abstract]   [Full Text] [Related]  

  • 13. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
    Peffault de Latour R; Kulasekararaj A; Iacobelli S; Terwel SR; Cook R; Griffin M; Halkes CJM; Recher C; Barraco F; Forcade E; Vallejo JC; Drexler B; Mear JB; Smith AE; Angelucci E; Raymakers RAP; de Groot MR; Daguindau E; Nur E; Barcellini W; Russell NH; Terriou L; Iori AP; La Rocca U; Sureda A; Sánchez-Ortega I; Xicoy B; Jarque I; Cavenagh J; Sicre de Fontbrune F; Marotta S; Munir T; Tjon JML; Tavitian S; Praire A; Clement L; Rabian F; Marano L; Hill A; Palmisani E; Muus P; Cacace F; Frieri C; van Lint MT; Passweg JR; Marsh JCW; Socié G; Mufti GJ; Dufour C; Risitano AM;
    N Engl J Med; 2022 Jan; 386(1):11-23. PubMed ID: 34986284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
    McQuilten Z; Heritier S; Fox L; Fox V; Young L; Blombery P; Cunningham I; Curnow J; Higgins A; Hiwase DK; Filshie R; Firkin F; Lacaze P; Mason K; Mills AK; Pepperell D; Patil S; Stevenson W; Szer J; Waters N; Wilson K; Ting S; Wood E
    BMJ Open; 2024 Jan; 14(1):e076246. PubMed ID: 38238183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
    Jie M; Fu L; Li S; He Y; Yao J; Cheng X; Zhang L; Zheng J; Zhang R; Wu R
    Pediatr Hematol Oncol; 2021 Oct; 38(7):647-657. PubMed ID: 33798022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of eltrombopag in severe aplastic anemia.
    Scheinberg P
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):450-456. PubMed ID: 30504345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
    Imada K; Obara N; Iida H; Imajo K; Maeda T; Usuki K; Fanghong Z; Hombo Y; Tajima T; Kumagai A; Matsuda A; Nakao S
    Intern Med; 2021 Apr; 60(8):1159-1168. PubMed ID: 33229810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
    Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
    Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
    [No Abstract]   [Full Text] [Related]  

  • 19. Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world.
    Li R; Wang N; Chai X; Yang L; Liu K; He H; Lin S; Yang Y; Jia J; Zhang D; Gong Y; Shi J; He G; Li J
    Clin Exp Med; 2023 Oct; 23(6):2619-2627. PubMed ID: 36645546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for the treatment of aplastic anemia: current perspectives.
    Lum SH; Grainger JD
    Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.